SD
Therapeutic Areas
Zai Lab Pipeline
| Drug | Indication | Phase |
|---|---|---|
| zocilurtatug pelitecan (ZL-1310) | Small Cell Lung Cancer | Phase 3 |
| ZL-1503 | Atopic Dermatitis | Phase 1/2 (Inferred) |
| ZL-6201 | Solid Tumors | Phase 1 (Inferred) |
| AUGTYRO (repotrectinib) | NTRK-Positive Solid Tumors | Approved |
| COBENFY (xanomeline/trospium) | Schizophrenia | Approved |
Leadership Team at Zai Lab
RG
Rafael G. Amado, M.D.
President, Head of Global Research and Development
YC
Yajing Chen, Ph.D.
Chief Financial Officer
JS
Josh Smiley
President and Chief Operating Officer
SH
Shan He, Ph.D.
Senior Vice President, Chief Business Officer
AZ
Andrew Zhu
Chief Commercial Officer, Greater China
FT
F. Ty Edmondson, J.D.
Chief Legal Officer and Corporate Secretary
CC
Christine Chiou
Senior Vice President, Head of Investor Relations
JY
James Yan, M.D., Ph.D., DABT
Chief Operating Officer, Global R&D
PC
Prista Charuworn, M.D.
Vice President, Global Clinical Development, Neuroscience & Immunology (NSI)